Valneva initiates fourth antibody discovery program for Sanofi Pasteur

25 February 2014

European biotechnology company Valneva (Euronext: VLA) has initiated a fourth monoclonal antibody discovery program for Sanofi Pasteur, the vaccines division of French drug major Sanofi (Euronext: SAN), on its proprietary single-cell screening platform VivaScreen.

This is part of the agreement signed with Sanofi Pasteur in June 2010, granting the latter and its affiliates exclusive access to Valneva’s VivaScreen technology for the discovery of several human monoclonal antibodies targeting significant infectious diseases. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than 1 million euros ($1.4 million) in research and development, according to Valneva.

Valneva eligible for 35 million euros development milestones per infectious disease

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK